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Summary
 
CD4 T cells and interferon 
 
g
 
 (IFN-
 
g
 
) are required for clearance of murine cytomegalovirus
(MCMV) infection from the salivary gland in a process taking weeks to months. To explain the
inefficiency of salivary gland clearance we hypothesized that MCMV interferes with IFN-
 
g
 
 in-
duced antigen presentation to CD4 T cells. MCMV infection inhibited IFN-
 
g
 
–induced pre-
sentation of major histocompatibility complex (MHC) class II associated peptide antigen by
differentiated bone marrow macrophages (BMM
 
f
 
s) to a T cell hybridoma via impairment of
MHC class II cell surface expression. This effect was independent of IFN-
 
a
 
/
 
b
 
 induction by
MCMV infection, and required direct infection of the BMM
 
f
 
s with live virus. Inhibition of
MHC class II cell surface expression was associated with a six- to eightfold reduction in IFN-
 
g
 
induced IA
 
b
 
 mRNA levels, and comparable decreases in IFN-
 
g
 
 induced expression of invariant
chain (Ii), H-2Ma, and H-2Mb mRNAs. Steady state levels of several constitutive host mRNAs,
including 
 
b
 
-actin, cyclophilin, and CD45 were not significantly decreased by MCMV infec-
tion, ruling out a general effect of MCMV infection on mRNA levels. MCMV effects were
specific to certain MHC genes since IFN-
 
g
 
–induced transporter associated with antigen pre-
sentation (TAP)2 mRNA levels were minimally altered in infected cells. Analysis of early up-
stream events in the IFN-
 
g
 
 signaling pathway revealed that MCMV did not affect activation
and nuclear translocation of STAT1
 
a
 
, and had minor effects on the early induction of IRF-1
mRNA and protein. We conclude that MCMV infection interferes with IFN-
 
g
 
–mediated in-
duction of specific MHC genes and the Ii at a stage subsequent to STAT1
 
a
 
 activation and nu-
clear translocation. This impairs antigen presentation to CD4 T cells, and may contribute to
the capacity of MCMV to spread and persist within the infected host.
 
H
 
uman cytomegalovirus (HCMV)
 
1
 
 is a major cause of
morbidity and mortality in immunocompromised in-
dividuals. Studies using murine cytomegalovirus (MCMV),
which serves as a useful animal model for HCMV, have
demonstrated that MCMV infection provokes strong re-
sponses by both innate and specific arms of the immune
system. However, even in the immunocompetent host,
MCMV; (
 
a
 
) causes disseminated acute infection; (
 
b
 
) persis-
tently produces infectious virus within the salivary gland
for weeks to months after induction of specific immunity;
and (
 
c
 
) establishes a life-long latent state. This suggests that
the virus is able to evade or modify responses by the im-
mune system.
Multiple components of the innate and specific immune
responses are active during acute MCMV infection. IFN-
 
a
 
/
 
b
 
, TNF-
 
a
 
, IL-12, and IFN-
 
g
 
 contribute to the control
of MCMV during initial stages of infection (1–5). NK cells
contribute to control of MCMV infection (6) through pro-
duction of IFN-
 
g
 
 (3, 4) and cytotoxicity (7). Specific im-
mune function is required for protection from virus-induced
mortality (8). CD8 T cells mediate clearance of infectious
virus from most peripheral organs and confer protective
immunity (9). However, CD4 T cells can effectively clear
MCMV infection from peripheral organs in the absence of
CD8 T cells (10). Clearance of MCMV from the salivary
gland involves CD4 T cells (11) and IFN-
 
g
 
 (1).
Both MCMV and HCMV have evolved mechanisms for
evading CD8 T cells and NK cells. Both viruses inhibit
 
1
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MHC class I expression on infected cells (12–16). Similarly,
both MCMV and HCMV interfere with NK cell activity
through the actions of virally encoded MHC class I ho-
mologs (17, 18). Since CD4 T cells are also essential for
control of MCMV infection from salivary gland, it is not
surprising that MCMV inhibits priming of CD4 T cells in
vivo (19). However, mechanisms underlying CMV-medi-
ated inhibition of CD4 T cell activation have not been
completely defined. HCMV-induced IFN-
 
b
 
, as well as di-
rect infection, inhibits IFN-
 
g
 
–induced MHC class II ex-
pression in endothelial cells (20, 21). HCMV also alters
MHC class II expression in cultured human peripheral blood
macrophages (M
 
f
 
s; reference 22). Similarly, MCMV-induced
IFN-
 
a
 
/
 
b
 
 inhibits MHC class II expression on M
 
f
 
s during
the innate immune response (23).
M
 
f
 
s are important in the pathogenesis of both HCMV
and MCMV. Key functions of M
 
f
 
s include presentation of
antigen to CD4 T cells via MHC class II and secretion of
cytokines. M
 
f
 
s are a site of MCMV replication in multiple
sites (24–26). Dissemination of MCMV (and likely HCMV)
to secondary sites of infection is mediated by M
 
f
 
s or M
 
f
 
-
like cells within the blood (25–27). Monocytes and M
 
f
 
s are
a site of long-term latency for HCMV and MCMV (28–31).
In these studies, MCMV impaired IFN-
 
g
 
–induced
MHC class II–dependent antigen presentation by bone
marrow (BM)M
 
f
 
s. This effect was due to the failure of
IFN-
 
g
 
 to efficiently induce mRNAs for IA
 
b
 
, invariant chain
(Ii), H-2Ma, and H-2Mb in infected cells, whereas quanti-
ties of transporter associated with antigen presentation
(TAP)2 mRNA were unaltered by infection. This effect on
MHC class II–mediated antigen presentation may contrib-
ute to the persistence of MCMV in the host, particularly in
the salivary gland, where CD4 T cells play a critical role.
 
Materials and Methods
 
Animals, Media, and BMM
 
f
 
 Culture.
 
4–12-wk-old 129Ev/Sv
and IFN
 
ab
 
 receptor–deficient (IFNR-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
) mice (32) were
housed in a Biosafety Level 2 facility at Washington University in
accordance with all Federal and University policies. Sentinel ani-
mals were negative for adventitious mouse pathogens by serol-
ogy. Virus stocks were grown and diluted in low endotoxin
(
 
,
 
0.025 ng/ml) DME containing 10% FCS (DME 10%; refer-
ence 3). BMM
 
f
 
s were prepared as previously described (23) and
were at least 95% F4/80 positive (data not shown). BMM
 
f
 
 cul-
tures were mock infected or infected with MCMV or UV-inacti-
vated MCMV, at a multiplicity of infection (MOI) of 5.0 unless
otherwise stated, for 1 h at 37
 
8
 
C in 5% CO
 
2
 
 with rocking every 5
min. After infection, cells were treated with IFN-
 
g
 
 (100 IU/ml;
Genentech, San Francisco, CA) or medium alone for various pe-
riods of time while incubating at 37
 
8
 
C in 5% CO
 
2
 
. Cells were
harvested by scraping, then fixed, and analyzed for IA
 
b
 
 expression
by flow cytometry. BMM
 
f
 
 viability was determined by trypan
blue exclusion.
 
Viruses and Viral Assays.
 
MCMV (American Type Culture
Collection [ATCC] No. VR-194, Lot 10) was grown, inacti-
vated by UV irradiation, and titered by plaque assay in BALB/
3T12-3 fibroblasts (ATCC, CCL 164; reference 3). Recombi-
nant MCMV expressing bacterial 
 
b
 
-galactosidase (RM427; refer-
 
ence 25) was a gift of Dr. Edward Mocarski (Stanford University,
Stanford, CA). 3T12 cells as well as MCMV stocks were negative
for mycoplasma using the Mycoplasma TC test kit (Gen-Probe,
San Diego, CA).
 
Analysis of Cell Surface Protein Expression.
 
Flow cytometry was
performed as previously described (3, 23) on an Epics flow cy-
tometer (Coulter, Miami, FL) using XL analysis software (Coulter)
or WinMDI 2.0 (Joseph Trotter, San Diego, CA). IA
 
b
 
 high and
low BMM
 
f
 
 were separated by fluorescent activated cell sorting
on a FACS
 
Ò
 
 Vantage fluorescent activated cell sorter (Becton
Dickinson, San Jose, CA). 
 
b
 
-galactosidase expression in sorted
cells was detected by 5-bromo-4-chloro-3 indolyl-
 
b
 
-
 
d
 
-galacto-
pyranoside staining (33).
 
Supernatant Transfer Studies.
 
Wild-type 129 BMM
 
f
 
s were ei-
ther mock infected or infected with MCMV for 48 h. Superna-
tants were ultracentrifuged for 30 min at 100,000 
 
g
 
 to remove
free virus as confirmed by plaque assay, and then placed on naive
cultures of wild-type or IFN-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
 BMM
 
f
 
s at 2 ml/plate in
60-mm dishes (Sarstedt, Newton, NC) for 1 h. In additional groups,
MCMV was added to the cultures at an MOI of 5.0. After 1 h of
incubation, IFN-
 
g
 
 (100 IU/ml) was added and culture volumes
were raised to 3 ml with fresh medium. Cultures were incubated
at 37
 
8
 
C for 48 h and were assayed for IA
 
b
 
 expression.
 
Electrophoretic Mobility Shift Assays.
 
BMM
 
f
 
s were either mock
infected or infected with MCMV for 1 h at 37
 
8
 
C. For STAT1
 
a
 
activation, cells were harvested at 1, 24, and 48 h after infection.
10
 
6
 
 cells were suspended in endotoxin free PBS (Sigma Chemical
Co., St. Louis, MO) containing 10% FCS, and were treated with
IFN-
 
g
 
 at concentrations ranging from 0.5 to 1,000 IU/ml for 10
min. Nuclear extracts were prepared and assayed by electrophoretic
mobility shift assay (EMSA) against a 
 
32
 
P-labeled oligonucleotide
probe derived from the IFN-
 
g
 
 activating sequence of the Fc
 
g
 
RI
promoter (34). Anti-STAT1 super-shift assays were performed by
incubation of 2 
 
m
 
g of STAT1 (p91) specific antiserum (Santa
Cruz Biotechnology, Santa Cruz, CA) with the nuclear extract/
probe mixture for 45 min at 25
 
8
 
C before acrylamide gel electro-
phoresis. For analysis of IRF-1 DNA-binding activity, BMM
 
f
 
were removed from medium containing L cell conditional me-
dium (23) for 15 h before infection with MCMV for 1 h followed
by treatment with IFN-
 
g
 
 (100 IU/ml) for an additional 4 h. Nu-
clear extracts were generated from 10
 
6
 
 cells (34) and assayed for
IRF-1 DNA binding activity by EMSA using a 
 
32
 
P-labeled oligo-
nucleotide containing the IFN response factor (IRF)-E of the mu-
rine (2
 
9
 
-5
 
9
 
) oligoadenylate synthase promoter (35). Super-shift assays
for IRF-1 were performed by adding 2 
 
m
 
g of anti–murine IRF-1
polyclonal antisera (Santa Cruz Biotechnology) to mixtures of ex-
tract and probe and incubating at 25
 
8
 
C for 45 min before analysis.
 
Northern Blot Analysis.
 
Total cellular RNA was harvested
from BMM
 
f
 
 cultures using RNAzol (Tel-Test Inc., Friend-
swood, TX) and analyzed by Northern blot hybridization (36).
PCR-derived probes used for these studies included a 300-bp
fragment of the murine IA
 
b
 
 beta chain (5
 
9
 
-ccggaattcgccagtgcctc-
cagaggtgacagtgtatc; 3
 
9
 
-cgcggatccccatgccacagaaacaggtctcaggag), a
rat 
 
b-actin fragment (59-tatggagaagatttggcacc; 39-gtccagacgcag-
gatggcat; gift of Dr. J. Milbrandt, Washington University) and a
226-bp fragment of mouse Ii p33 cDNA (59-agctctgtacaccggt-
gtctctgtcc; 39-gacattggacgcatcagcaagggag; gift of Dr. E. Unanue,
Washington University, St. Louis, MO). The following cDNAs
were also used to generate probes: murine IRF-1 (37), rat cyclo-
philin (38), murine CD45 (provided by Dr. M. Thomas, Wash-
ington University), TAP1 (39), TAP2 (40), H-2Ma, and H-2Mb
(41) (the latter four gifts of Dr. J. Monaco, University of Cincin-
nati, Cincinnati, OH). All probes were radiolabeled using the1039 Heise et al.
Megaprime DNA Labeling System (Amersham Corp., Arlington
Heights, IL). Loading of mRNA was normalized against 28S ri-
bosomal RNA (42) or against cyclophilin or b-actin mRNA lev-
els. Northern blot hybridizations were quantitated on a Phosphor-
imager (Molecular Dynamics, Sunnyvale, CA). Fold reduction of
IFN-g–induced mRNA levels by MCMV was computed as
[(IFN-g–stimulated signal in uninfected cells) 2 (unstimulated
signal in uninfected cells)]/[(IFN-g–stimulated signal in infected
cells) 2 (unstimulated signal in infected cells)], after signal was
normalized to 28S rRNA or cyclophilin levels.
Antigen Presentation Assays. BMMfs were mock infected or
infected with MCMV and treated with IFN-g (100 IU/ml) for
24 h. Cells were then harvested, counted, and incubated in 1%
paraformeldahyde in RPMI 10% FCS for 15 min at 258C. The
fixed cells were washed vigorously, plated at 103, 5 3 103, 104, or
5 x 104 cells/well, and incubated with the T cell hybridoma B11
(IAb-restricted,  b-galactosidase peptide 429-441–specific, pro-
vided by Dr. Paul Allen, Washington University) in the presence
of b-galactosidase peptide 429-441, control peptide, or medium
alone for 24 h. Supernatants were then assayed for IL-2 by prolif-
eration of the IL-2–dependent cell line CTLL2 as measured by
[3H]thymidine incorporation (43). No IL-2 production above
background was observed using a control peptide derived from
the MCMV MCK-1 open reading frame (VVLVVSTVADL-
REPC; reference 44) at 10, 1, or 0.1 mM (data not shown).
Results
MCMV Inhibition of Antigen Presentation to CD4 T
Cells. We examined IFN-g–stimulated presentation of
peptide antigen to CD4 T cells by primary BMMfs after
infection with MCMV. Primary cells were used because
previous studies of MCMV regulation of MHC class I ex-
pression had revealed differences between cell lines and pri-
mary cells (15). Mfs were either mock infected or infected
with MCMV, treated with IFN-g for 24 h, fixed, and
tested for the ability to present peptide antigen (Fig. 1 A).
IFN-g treatment of Mfs resulted in effective presentation
of b-galactosidase peptide (429–441) to the T cell hybri-
doma B11, whereas MCMV infection abolished IFN-g–
induced antigen presentation. The antigen presenting cell,
rather than the T cell hybridoma, was impaired by virus
since (a) Mfs were fixed before incubation with T cells,
and (b) addition of fixed MCMV infected Mfs did not ef-
ficiently inhibit the capacity of uninfected Mfs to present
peptide antigen (Fig. 1 A). Cell surface IAb levels were
evaluated by flow cytometry, since decreased IAb expres-
sion might explain defective antigen presentation. MCMV-
infected Mfs failed to respond to IFN-g stimulation by
upregulation of cell surface IAb (Fig. 1 B).
MCMV Blockade of IFN-g Induction of IAb Cell Surface Ex-
pression. MCMV and HCMV infection at a low MOI
impair IFN-g–induced MHC class II expression via induc-
tion of IFN-a/b (20, 23). To evaluate MCMV’s effects on
Mf responsiveness to IFN-g independently of IFN-a/b,
all experiments were performed at a high MOI in Mfs de-
rived from mice carrying a null mutation in the IFN-a/b
receptor (IFN-a/bR2/2; reference 32). These Mfs do not
Figure 1. MCMV infection
impairs IFN-g–enhanced pep-
tide presentation by MHC class
II. 129 mouse BMMfs were
mock infected or infected with
MCMV at an MOI of 5.0 for 1 h,
and stimulated with IFN-g (100
IU/ml) or medium alone. After
24 h BMMfs were assayed for
ability to present peptide anti-
gen, and analyzed for MHC class
II expression by flow cytometry.
(A) Mfs were plated at 103, 5 3
103, 104, and 5 3 104 cells per
well, and incubated with the T
cell hybridoma B11 (b-galactosi-
dase 429-441, IAb-restricted) in
the presence of b-galactosidase
peptide (429–441) at a concen-
tration of 10 mM. Supernatants
were harvested and assayed for
IL-2 content using [3H]thymi-
dine incorporation by CTLL2
cells. Mock 1 IFN-g and
MCMV  1 IFN-g BMMfs were
mixed 1:1 and assayed as a con-
trol for potential toxic effects of
MCMV-infected cells. Similar
data was obtained at a peptide concentration of 1.0 mM. Data is from one of
two similar experiments. All groups were plated in triplicate and are
shown as mean cpm 6 SEM. (B) Cell surface expression of the MHC
class II molecule IAb on BMMfs infected with MCMV and stimulated
with IFN-g as above was measured by flow cytometry.
Figure 2. Infectious MCMV impairs IFN-g–induced MHC class II ex-
pression on Mfs in a dose-dependent manner. IFN-a/bR2/2 BMMfs
were mock infected or infected with live or UV-inactivated MCMV at
an MOI of 1.5, 3.0, or 6.0 for 1 h before addition of 100 IU/ml IFN-g.
Mfs were harvested 48 h after infection and assayed for MHC class II ex-
pression (IAb) by flow cytometry. Shown is one of three experiments,
each of which yielded similar results.1040 MCMV Inhibition of IFN-g–induced MHC Gene Expression
respond to IFN-a/b stimulation, but do respond to stimu-
lation with IFN-g as measured by induction of IAb expres-
sion (Fig. 1 B and Fig. 2; references 23, 32). Infection of
IFN-a/bR2/2 Mfs with increasing doses of MCMV re-
sulted in a progressive decrease in the percentage of cells
expressing IFN-g–induced IAb (Fig. 2). Cell viability in the
MCMV-infected Mf cultures was .95% at 72 h after in-
fection. Live virus was required for inhibition of IAb ex-
pression, since UV-inactivated MCMV, even at a MOI of
6.0, had no effect on Mf IAb expression (Fig. 2).
Inhibition of MHC Class II Induction Correlates with Direct
Infection of Mfs. MCMV-mediated inhibition of IFN-g–
induced IAb expression was dependent on viral dose (Fig. 2),
which suggested a role for direct infection. To address this
possibility, IFN-a/bR2/2 Mfs were infected with RM427
(25), a recombinant MCMV expressing b-galactosidase un-
der the MCMV ie1/ie2 promoter/enhancer at an MOI of
0.6, and treated with IFN-g. Cells were fixed 48 h after in-
fection, stained for IAb expression, and separated into IAb
high and low populations by fluorescent activated cell sort-
ing (Fig. 3 A). IAb low Mfs were enriched for b-galatosi-
dase positive (infected) cells (Fig. 3, A and B), whereas the
IAb high cells were only 0.5–2.5% positive for b-galactosidase.
This demonstrated that IAb expression is low in MCMV-
infected BMMfs. However, over several experiments,
b-galactosidase was detected in ,100% of IAb low cells,
raising the possibility that a soluble mediator might con-
tribute to low class II expression in b-galactosidase–nega-
tive cells.
To determine whether soluble factors played a role in
MCMV’s inhibition of IAb induction in IFN-a/bR2/2
Mfs, supernatant transfer studies were performed. Super-
natants from wild-type 129 Mfs infected with MCMV or
mock infected for 48 h were ultracentrifuged to remove
free virus and placed on naive Mf cultures derived from
either wild-type 129 or IFN-a/bR2/2 mice. IFN-g was
added to these secondary cultures, and after 48 h, IAb ex-
pression was evaluated (Fig. 4). As expected from our pre-
vious work (23), supernatant from MCMV-infected Mfs
inhibited IFN-g–induced IAb expression on wild-type
Mfs, but not on IFN-a/bR2/2 Mfs (Fig. 4), confirming
that MCMV-induced IFN-a/b can inhibit IFN-g–induced
MHC class II expression. However, there was no evidence
for a soluble mediator affecting IAb expression in MCMV-
infected IFN-a/bR2/2 Mf cultures (Fig. 4). Therefore,
direct infection of the Mf, rather than a soluble mediator,
is likely to explain MCMV’s effects on MHC IAb expres-
sion.
MCMV Inhibits IFN-g–induced MHC Class II and Invari-
ant Chain mRNA Expression. IFN-g induction of MHC
class II expression occurs at the level of gene transcription
(45), and studies in HCMV-infected endothelial cells have
shown that HCMV infection regulates MHC class II
mRNA levels (21). We therefore evaluated MCMV’s ef-
Figure 3. MCMV-infected
BMMfs express low levels of
MHC class II. IFN-a/bR2/2
BMMfs were either mock in-
fected or infected with recombi-
nant MCMV expressing b-galac-
tosidase (RM427) at an MOI of
0.6. 1 h after infection, cells were
treated with IFN-g (100 IU/ml)
or medium alone for 48 h. Cells
were harvested, stained for MHC
class II (IAb) expression, and sep-
arated into MHC class II high
and low populations by fluorescent
activated cell sorting. The numbers
of cells expressing b-galactosidase
in total and sorted cell popula-
tions was determined by 5-bromo-
4-chloro-3-indolyl-b-d-galacto-
pyranoside (x-gal) staining. (A)
Mock-infected or infected cells
(top panels), and IAb high and low
populations from infected cul-
tures (bottom panels) were stained
for IAb. The dotted line repre-
sents staining on unstimulated,
mock-infected cells. The solid
line depicts staining of IFN-g–
treated groups. (B) x-gal staining
of mock- or MCMV-infected,
and MHC class II high and low,
populations is shown from one
of three similar experiments.1041 Heise et al.
fect on mRNA levels of an IFN-g–induced MHC class II
gene, IAb. Infection with MCMV, but not UV-inactivated
MCMV, decreased IFN-g–induced accumulation of IAb
mRNA 6–8-fold at 24 h and 5–.10-fold at 48 h after in-
fection (Fig. 5).
Although a 6–8-fold reduction of IFN-g–induced IAb
mRNA accumulation within MCMV-infected cells ex-
plained a portion of the effects of MCMV infection on an-
tigen presentation (Fig. 1 A), it did not plausibly account
for the at least 30-fold loss of cell surface expression of IAb
(Figs. 1 B, 2, 3, 4). Therefore, we examined the effect of
MCMV on expression of another IFN-g–inducible gene, Ii,
which is essential for efficient cell surface expression of MHC
class II (46, 47). Northern blot hybridization showed that
IFN-g–induced Ii transcript levels are reduced 5–.10-fold
at 24 h and .10-fold at 48 h in MCMV-infected BMMf
cultures. The combined effect of MCMV infection on
IFN-g–induced IAb and Ii mRNA accumulation plausibly
explains most or all of the decreased MHC class II expres-
sion on MCMV-infected Mfs.
To address the possibility that MCMV’s reduction of IAb
and Ii mRNA levels was due to a general effect on host
mRNA, levels of several constitutive host mRNAs were
evaluated. MCMV infection for up to 48 h did not signifi-
cantly decrease levels of b-actin (Fig. 5, A and B), cyclo-
philin (see Fig. 8), or CD45 (data not shown) mRNAs as
measured against a 28S RNA loading control. In contrast,
treatment of BMMfs with actinomycin D for 5–10 h re-
vealed diminished b-actin, cyclophilin, and CD45 mRNA
levels compared to untreated cells (data not shown), dem-
onstrating that the half lives of these mRNAs were short
enough for us to detect significant MCMV induced alter-
ation in their stability. Thus, inhibition of IFN-g–induced
IAb and Ii mRNA accumulation is not solely due to a gen-
eral effect on mRNA levels by MCMV.
MCMV Does Not Alter IFN-g Induction of STAT1a
DNA Binding Activity. IFN-g initiates a cascade of events
that leads to MHC class II mRNA accumulation, any one
of which could, a priori, be altered by MCMV infection.
We examined the effect of MCMV on an essential early
event in IFN-g receptor signaling, activation and nuclear
translocation of the latent cytoplasmic transcription factor
STAT1a. Activation of STAT1a is essential for IFN-g in-
duction of MHC class II expression (48). Mfs were either
mock infected or infected with MCMV for 1, 24, or 48 h
before stimulation with IFN-g, preparation of nuclear ex-
tracts, and evaluation of STAT1a binding activity by
EMSA (Fig. 6). The presence of STAT1a in the activated
complex was confirmed by super-shift with antibody
against STAT1a (Fig. 6), whereas antibody to IRF-1 did
not result in retardation of the complex (data not shown).
IFN-g treatment resulted in comparable levels of STAT1a
DNA binding activity in both mock- and MCMV-infected
Mfs, at 1, 24 (Fig. 6), and 48 (data not shown) h after in-
Figure 4. Supernatants from MCMV-infected Mfs inhibit IFN-g in-
duction of MHC class II on normal but not IFN-a/bR2/2 BMMfs.
Wild-type 129 BMMfs were either mock infected or infected with
MCMV at an MOI of 5.0. 48 h after infection, supernatants were re-
moved, ultracentrifuged to remove free virus, and placed on naive cul-
tures of either 129 or IFN-a/bR2/2 BMMfs. At the time of supernatant
transfer, additional cultures were infected with MCMV (MOI 5 5.0) as
positive controls. After 1 h of incubation with the supernatants or
MCMV, cells were treated with IFN-g (100 IU/ml), incubated for 48 h,
and harvested. MHC class II (IAb) expression was determined by flow cy-
tometry. Shown is data from one of two experiments yielding similar re-
sults. (US, unstained).
Figure 5. MCMV infection
reduces IFN-g–induced MHC
class II and Ii mRNA levels.
IFN-a/bR2/2 BMMfs were
either mock infected or infected
with MCMV or UV-inactivated
MCMV at an MOI of 5.0. 1 h
after infection, cells were treated with medium alone or with IFN-g (100
IU/ml). Total cellular RNA was harvested at either 24 or 48 h after in-
fection and analyzed by Northern blot hybridization for the IAb beta
chain or Ii. b-actin hybridization is also shown. Similar results were ob-
tained in three separate experiments.
Figure 6. STAT1a activation
and nuclear translocation after
IFN-g stimulation is normal in
MCMV-infected Mfs. IFN-a/
bR2/2 BMMfs were infected
with MCMV at an MOI of 5.0
or mock infected for 1 or 24 h.
Harvested cells were incubated
with IFN-g for 10 min and nu-
clear extracts were prepared. Ex-
tracts were assayed for STAT1a
activation by EMSA against a
32P-labeled IFN-g activation se-
quence containing oligonucle-
otide derived from the murine FcgR1 promoter. The presence of
STAT1a in the complex was determined by antibody super-shift using
STAT1a-specific antiserum. Shown are STAT1a activation by IFN-g at
1 h (100 IU/ml IFN-g) or 24 h (5 IU/ml IFN-g) after infection. Similar
results were obtained in four separate experiments.1042 MCMV Inhibition of IFN-g–induced MHC Gene Expression
fection. STAT1a activation was also equivalent in mock-
and MCMV-infected Mfs after treatment with IFN-g at
doses as low as 0.5 IU/ml (data not shown). We conclude
that the IFN-g signaling pathway remains intact through
STAT1a activation in MCMV-infected BMMfs.
MCMV Effects on IFN-g Induction of IRF-1. To directly
assess the effects of MCMV on the transactivating function
of STAT1, we examined IFN-g induction of IRF-1
mRNA and protein. IRF-1 is rapidly induced at the tran-
scriptional level after IFN-g stimulation in a STAT1a-
dependent manner (48), with maximal mRNA expression
by 2 h of cytokine treatment (49). Mfs were mock in-
fected or infected with MCMV at an MOI of 5.0 for 3 h
and treated with IFN-g (100 IU/ml) for the final 2 h of in-
fection. Northern blot analysis showed that induction of
IRF-1 mRNA accumulation by IFN-g in MCMV-infected
Mfs was 70–90% that of uninfected cells (Fig. 7 A). To as-
sess MCMV effects on expression of IRF-1 protein, we as-
sayed nuclear extracts of Mfs that were mock or MCMV
infected for a total of 5 h, with IFN-g treatment during the
final 4 h for binding to the IRF-E element of the murine
(29-59) oligoadenylate synthase promoter (35) by EMSA.
IFN-g treatment induced IRF-1 DNA binding activity in
MCMV-infected cells (Fig. 7 B) as confirmed by super-shift
of the complex after incubation with anti–IRF-1, but not
anti-STAT1a, antiserum. IFN-g–induced IRF-1 DNA
binding activity was decreased by at most 50% in MCMV-
infected Mfs compared to mock-infected Mfs. IRF-1
DNA binding activity could also be induced by IFN-g in
Mfs that had been infected with MCMV for 24 h (data not
shown).
MCMV Inhibits IFN-g Induction of Specific MHC Genes.
To assess the specificity of the block of IFN-g signaling
caused by MCMV infection, we examined levels of several
IFN-g–induced transcripts in addition to IAb, Ii, and IRF-
1. IFN-a/bR2/2 M f s were infected with MCMV or
UV-inactivated virus, or mock infected for 24 or 48 h in
the presence or absence of IFN-g, and mRNA levels were
analyzed by Northern blot hybridization. IFN-g induction
of H-2Ma and H-2Mb expression was significantly inhib-
ited by MCMV at 24 h (Fig. 8), whereas IFN-g–induced
TAP1 mRNA levels were decreased to a lesser extent.
However, TAP2 mRNA levels were not significantly de-
creased by MCMV infection (Fig. 8). Northern blot data
from 48-h infections were similar to that of 24-h infections
(data not shown). The lack of effect on IFN-g induction of
TAP2 transcript levels by MCMV demonstrated that
MCMV selectively affects expression of a subset of IFN-g–
inducible genes.
Discussion
CD4 T cells are required for clearance of salivary gland
MCMV infection (11), yet infectious virus is found in the
salivary gland for many weeks after acute infection, sug-
gesting that MCMV antagonizes CD4 T cell function in
some manner. It has also been shown that MCMV impairs
CD4 T cell priming in vivo (19). These observations led us
to examine the effects of MCMV on presentation of anti-
gen to CD4 T cells and induction of genes associated with
MHC class II cell surface expression.
MCMV inhibited IFN-g induction of IAb and Ii gene
expression in IFN-a/bR2/2 BMMfs, resulting in defec-
tive antigen presentation to CD4 T cells. Inhibition of IAb
expression required direct infection of the Mfs with live
virus. Early IFN-g signaling events including STAT1a ac-
tivation and IRF-1 induction remained largely intact in
MCMV-infected cells. Further analysis showed that
MCMV infection altered the induction of multiple genes
encoding proteins important for MHC class II expression
and/or presentation of peptide antigen to CD4 T cells,
Figure 7. IRF-1 mRNA and
DNA binding activity is induc-
ible by IFN-g in MCMV-infected
Mfs. (A) IFN-a/bR2/2 were ei-
ther mock infected or infected
with MCMV at an MOI of 5.0
for 3 h. Cultures were treated
with IFN-g for the final 2 h of
infection and assayed for IRF-1
mRNA levels by Northern blot
hybridization. Shown is one of
two experiments yielding similar
results. (B) IFN-a/bR2/2 BM-
Mfs were infected with MCMV
at an MOI of 5.0 or mock in-
fected for 5 h. Cells were treated
with IFN-g for the final 4 h of
infection and nuclear extracts
were prepared. IRF-1 DNA bind-
ing activity was assessed by incu-
bating extract with a 32P-labeled
IRF-E oligonucleotide probe,
which was then analyzed by
EMSA. The presence of IRF-1
within the complex was con-
firmed by incubation with anti-
serum against murine IRF-1 or
STAT1a. Three separate experi-
ments yielded similar results.
Figure 8. MCMV infection
inhibits H-2Ma, H-2Mb, and
TAP1 mRNA expression, but
not IFN-g–induced TAP2
mRNA expression. IFN-a/
bR2/2 BMMf were either
mock infected or infected with
MCMV or UV-inactivated
MCMV at an MOI of 5.0 in the
presence or absence of IFN-g
(100 IU/ml) for 24 h. Total cel-
lular RNA was harvested and
analyzed by Northern blot. Blots
were probed using radiolabeled
probes for murine TAP1, TAP2,
H-2Ma, H-2Mb, cyclophilin,
and 28S ribosomal RNA. Shown
is one of three experiments
which yielded similar results.1043 Heise et al.
while another IFN-g–inducible MHC gene was largely
unaffected.
Effects of MCMV on MHC Class II Antigen Presentation.
MCMV impaired the ability of IFN-g to induce expression
of mRNAs encoding multiple genes important for antigen
presentation to CD4 T cells. These genes included the
MHC class II allele IAb, as well as the Ii p33 subunit and
the peptide-loading protein subunits H-2Ma and H-2Mb.
Although the 6–8-fold reduction of IFN-g–induced IAb
mRNA levels observed in the setting of MCMV infection
undoubtedly contributed to loss of cell surface expression
of IAb (e.g., Fig. 1 B), it was possible that additional factors
accounted for the near complete inhibition of IAb expres-
sion. Ii is required for maximal cell surface expression of
MHC class II proteins (46, 47), and induction of Ii by IFN-g
was significantly inhibited in MCMV-infected cells. De-
creased expression H-2Ma and H-2Mb might also contrib-
ute to impaired MHC class II peptide presentation, since
these proteins are necessary for optimal loading of peptide
onto MHC class II molecules (50–52). However, loss of
H-2Ma and H-2Mb expression probably did not contrib-
ute to decreased detection of cell surface IAb, as the anti-
body 25-9-17S detects IAb loaded with the class II Ii-asso-
ciated peptide, CLIP (50–52).
Implications of b-herpesvirus Impairment of Antigen Presenta-
tion to CD4 T Cells. Three lymphocyte classes (CD4 and
CD8 T cells, and NK cells) are important for resistance to
CMV during acute infection. CD8 T cells promote
MCMV clearance and mediate protective immunity (9),
and are also important for control of HCMV (53). As a
countermeasure, both MCMV and HCMV inhibit antigen
presentation to CD8 T cells by limiting MHC class I pro-
tein–dependent antigen presentation (12–16). HCMV and
MCMV prevent decreased expression of MHC class I on
infected cells from triggering NK cells via expression of cell
surface MHC class I homologs (17, 18). CD4 T cells and
IFN-g are important for clearance of virus from the salivary
gland (1, 11), but priming of CD4 T cells is inhibited in
MCMV-infected mice (19). The findings in this paper de-
lineate a potential mechanism by which MCMV might im-
pair CD4 T cell activation and avoid recognition by this
third important class of lymphocytes.
We believe that viral impairment of IFN-g–induced an-
tigen presentation by Mfs in particular has important im-
plications for acute and chronic MCMV pathogenesis. Mfs
are involved in dissemination of MCMV and HCMV (25–
27) and yet they are activated by IFN-g during acute
MCMV infection (3, 23). IFN-g inhibits MCMV growth
in Mfs and other cells (3, 54, 55). How then does the virus
disseminate in a cell activated by an anti-viral cytokine? We
propose that signaling by IFN-g is inhibited in Mfs if the
virus is able to infect them and express protein before acti-
vation by IFN-g. This would allow the virus to take ad-
vantage of the mobility of the Mfs for dissemination,
while minimizing the effects of IFN-g on viral growth and
enhancement of immune induction. Our hypothesis is sup-
ported by the observation that Mf-like cells that dissemi-
nate MCMV are MHC class II negative (25), whereas the
majority of Mfs responding to MCMV in inflammatory
exudates from immunocompetent mice express high levels
of MHC class II and are uninfected (3, 23). Furthermore,
we have preliminary data for a role of IFN-g in controlling
chronic MCMV infection (Presti, R., J. Pollock, and H.W.
Virgin, unpublished data). Since one site of MCMV and
HCMV latency is cells of the monocyte/Mf lineage, inter-
ference with IFN-g signaling in latently infected cells may
permit viral escape from IFN-g’s antiviral effects, allowing
reactivation and subsequent growth.
Mechanism of Inhibition of IFN-g Induction of MHC Gene
Expression. We found that MCMV infection inhibits ex-
pression of specific IFN-g–induced genes. Other viruses
such as adenovirus have also been shown to alter IFN-medi-
ated gene induction. Adenovirus protein E1A may block
IFN-a signaling by inhibition of STAT2-dependent trans-
activation involving p300/CBP (56). In our studies,
MCMV inhibited IFN-g signaling distal to STAT1a acti-
vation since induction of STAT1a DNA binding activity
was normal in infected cells, and mRNA levels of IRF-1, a
gene transactivated by STAT1a were also near normal
early after IFN-g treatment. Constitutive and inducible ex-
pression of MHC class II, H-2Ma, H-2Mb, and Ii are de-
pendent on the class II transactivator (CIITA) (57–60).
MCMV significantly inhibits induced expression of all of
these genes. Therefore, one may speculate that a mecha-
nism of viral action is the specific impairment of expression
or function of CIITA.
Although there is a formal possibility that MCMV exerts
its effect at the level of mRNA stability, we doubt this for
two reasons. First, we saw little evidence of a general effect
of MCMV on mRNA stability in the presence or absence
of IFN-g over multiple experiments based on comparisons
of cyclophilin, b-actin, and CD45 mRNA levels. Second,
the effects of MCMV are specific to certain MHC genes.
Thus, if MCMV infection interferes with IFN-g induction
of MHC genes by destabilizing mRNAs, one would have
to argue that the effects are specific for certain transcripts
(e.g., IAb and Ii but not TAP2, b-actin, or cyclophilin).
We have documented a novel mechanism of immune
avoidance by CMV, selective blockade of IFN-g induction
of genes involved in antigen presentation to CD4 T cells.
Further characterization of MCMV’s block on IFN-g sig-
naling, and identification of the viral genes involved will
likely enhance understanding of CMV pathogenesis and
the antiviral functions of the immune system.
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